News Breaks |
|
|
| September 4, 2012 |
| 08:41 EDT |  | AMRN | Amarin announces notification of patent allowance
Amarin announced that the United States Patent and Trademark Office has published notification of a Notice of Allowance for U.S. Patent Application Serial Number 13/282,145, titled "Method of Treating Hypertriglyceridemia." The application includes claims intended to protect the Vascepa indication approved in July 2012 by the FDA based on Amarin's MARINE clinical trial results. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent would have term that expires no earlier than in 2030. After issuance, Amarin plans to list the patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. The application is part of an expanding patent portfolio for Amarin with seven patent applications now either issued, allowed or in advanced stages of prosecution with the USPTO and over 25 additional applications pending in the United States. Amarin is also pursuing patent applications related to Vascepa in multiple jurisdictions outside the United States. |
|
|
News For AMRN From The Last 14 Days Check below for free stories on AMRN the last two weeks. |
|
|
| May 23, 2013 |
| 11:55 EDT |  | AMRN | Options with decreasing implied volatility: AEGR PXP AMRN DSX ACT
 Subscribe for More Information |
|
| May 22, 2013 |
| 11:56 EDT | | AMRN | Options with decreasing implied volatility: WCRX NTI PXP AMRN BBY
|
|
| 06:07 EDT | | AMRN | Amarin announces patent allowance related to combination of Vascepa, Statin
Amarin announced that the United States Patent and Trademark Office has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/417,899 titled "Pharmaceutical Compositions Comprising EPA and a Cardiovascular Agent and Methods of Using the Same." This application includes claims intended to protect the Vascepa indication approved by the FDA based on Amarin's MARINE clinical trial results specifically those results seen in patients on statin therapy. The claims in this allowed application cover a method to reduce triglycerides in subjects having a triglyceride level of 500mg/dl to 1500mg/dl who are also receiving statin therapy using an amount of Vascepa effective to reduce triglycerides without substantially increasing low density lipoprotein cholesterol. |
|
| May 21, 2013 |
| 11:41 EDT | | AMRN | Options with decreasing implied volatility: SGMO WCRX NTI TSLA AMRN
|
|
| May 17, 2013 |
| 14:12 EDT | | AMRN | Amarin shares slip after FDA updates Orange Book
Subscribe for More Information |
|
| May 15, 2013 |
| 11:04 EDT |  | AMRN | Amarin management to meet with Lazard Capital
Meeting to be held in the Mid-Atlantic area on May 16 hosted by Lazard Capital. |
|
| May 13, 2013 |
| 12:52 EDT | | AMRN | Amarin strength attributed to MassHealth drug list addition
Subscribe for More Information |
|
| May 10, 2013 |
| 09:23 EDT |  | AMRN | Amarin continues to make progress with payors, says Leerink
Leerink reiterates an Outperform rating on shares of Amarin following the company's Q1 results. The firm believes Amarin continues to make good progress with payors and that Vascepa script trends are tracking well. |
|
|
|
|
|
